Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Gender and chemotherapy-related toxicity in colon cancer: an analysis of the PETACC-3 trial conducted by the EORTC GI-group

Date

08 Oct 2016

Session

Poster Display

Presenters

Valérie Cristina

Citation

Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370

Authors

V. Cristina1, J. Mahachie2, M. Mauer2, C. Csajka3, D. Cunningham4, E. van Cutsem5, A. Roth6, A.D. Wagner1

Author affiliations

  • 1 Département D'oncologie, Centre Hospitalier Universitaire Vaudois - CHUV, 1011 - Lausanne/CH
  • 2 Gi Group, EORTC, 1200 - Brussels/BE
  • 3 Division De Pharmacologie Clinique, Centre Hospitalier Universitaire Vaudois - CHUV, 1005 - Lausanne/CH
  • 4 Department Of Oncology, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, SM2 5PT - Sutton/GB
  • 5 Gastro-enterology, University Hospitals Leuven - Campus Gasthuisberg, Leuven/BE
  • 6 Group Cancer Gastro-intestinal, SAKK, 3008 - Bern/CH
More

Resources

Abstract 2167

Background

Drug metabolism is genetically determined. Gender is one of the factors responsible for the large interpatient variability in the dose-effect relationship of cytotoxics. Comparative data on the effect of gender on chemotherapy (CT)-related toxicity are lacking in colon cancer.

Methods

This is a retrospective analysis of data from the PETACC-3 trial: 2974 pts (55.7% men (m) and 44.3% women (f)) with stage II and III colon cancer were treated with adjuvant 5-fluorouracil/leucovorin alone (5FU/LV) or with irinotecan (FOLFIRI). Primary aim was to compare CT-related toxicity (according to NCIC-CTCG) in m and f. Clinical and hematologic adverse events (AEs) rates and frequency of dose reductions in m and f were compared by Fisher's exact test; survival outcomes by log-rank test. Subgroup analyses were performed according to age (

Results

Higher rates of all grade nausea (61.8 vs 53.7%, p 

Conclusions

In this trial, women demonstrated significantly greater rates of various hematological and non-hematological AEs, especially under treatment with FOLFIRI. Thus, AEs need to be reported according to gender in future clinical trials. Further data investigating the relationship between gender and CT efficacy and toxicity is required.

Clinical trial identification

Legal entity responsible for the study

EORTC GI Group

Funding

EORTC GI Group

Disclosure

D. Cunningham: Amgen, AstraZeneca, Bayer, Celgene, Medimmune, Merck Serono, Merrimack, Sanofi: Research funding to my institution. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings